The Technical Analyst
Viridian Therapeutics, [VRDN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Viridian Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-8.56% $13.03
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 817.86 mill |
| EPS: | -5.31 |
| P/E: | -2.45 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 62.77 mill |
| Avg Daily Volume: | 0.903 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.42x |
| Company: PE -2.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.792 (-86.25%) $-11.24 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 12.02 - 14.06 ( +/- 7.80%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Fairmount Funds Management Llc | Buy | 5 859 | Common Stock |
| 2024-03-28 | Fairmount Funds Management Llc | Buy | 21 999 | Series A Non-Voting Convertible Preferred Stock |
| 2024-03-28 | Fairmount Funds Management Llc | Sell | 5 859 | Common Stock |
| 2024-03-28 | Fairmount Funds Management Llc | Sell | 21 999 | Series A Non-Voting Convertible Preferred Stock |
| 2024-02-12 | Tousignant Jennifer | Buy | 0 |
| INSIDER POWER |
|---|
| 58.76 |
| Last 95 transactions |
| Buy: 5 352 885 | Sell: 1 550 540 |
Forecast:
16:00 - $13.03
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $13.03
Forecast 2: 16:00 - $13.03
Forecast 3: 16:00 - $13.03
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.03 (-8.56% ) |
| Volume | 0.770 mill |
| Avg. Vol. | 0.903 mill |
| % of Avg. Vol | 85.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VRDN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $17.81 | N/A | Active |
|---|
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2024-04-04 16:01:00 - Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn) (the “company” or “viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 102,000 shares of the company's common stock to.
2024-03-29 09:00:00 - Press Release
Viridian Shareholder Alert: Kaskela Law Llc Announces Investigation Of Viridian Therapeutics, Inc. (vrdn) And Encourages Investors To Contact The Firm
Philadelphia , march 29, 2024 /prnewswire/ -- kaskela law llc announces that it is investigating viridian therapeutics, inc. (nasdaq: vrdn) ("viridian") on behalf of the company's shareholders. the investigation seeks to determine whether viridian and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's shareholders in connection with recent corporate actions.
2024-03-06 16:01:00 - Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn) (the “company” or “viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 62,000 shares of the company's common stock to t.
2024-02-27 16:01:00 - Press Release
Viridian Therapeutics Highlights Recent Progress And Reports Fourth Quarter And Full Year 2023 Financial Results
Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended december 31, 2023. “throughout 2023, we delivered important clinical results across our ted portfolio, marking significant progress for the company,” said steve mahoney, viridian president.
2024-02-16 08:00:00 - Press Release
Viridian Therapeutics Appoints Jennifer Tousignant As Chief Legal Officer
Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn) (the “company” or “viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of jennifer tousignant to the role of chief legal officer. “i am very pleased to welcome jennifer to viridian to lead our legal team and join viridian's executive team ahead of an exciting set of milestones this year across our t.
Latest News
2024-03-19 18:51:50 - InvestorPlace
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
Inflation has been the scourge of American households since the Covid-19 disruption. But investors can attempt to beat rising prices with stocks under $20.
2024-02-28 10:56:09 - Zacks Investment Research
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to a 97.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-01-27 13:09:38 - 24/7 Wall Street
Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Overall, the number of notable insider purchases may have dwindled with the earnings-reporting season in full swing, but there were still some huge, headline-making buys in the past week or so.
2023-12-26 17:21:16 - CNBC Television
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
2023-12-12 08:00:00 - Seeking Alpha
Viridian: Market May Be Wrong In Its Disapproval
Viridian Therapeutics, Inc. stock has been on a downward trend since announcing complex data in July. The market may be wrong in its assessment. However, I have no big conviction as to market success, only trial success.
2023-11-13 18:47:33 - Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $0.86 per share a year ago.
2023-10-31 04:31:04 - Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?
Viridian Therapeutics, Inc. (VRDN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2023-08-08 18:56:54 - Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.
2023-07-19 10:07:00 - The Motley Fool
2 Growth Stocks Wall Street Analysts Think Can Double in Value
Viridian has a treatment for thyroid eye disease in the works that could be a potential blockbuster. Ginkgo Bioworks programs cells and has huge opportunities in many different industries.
2023-07-13 15:16:45 - Seeking Alpha
Viridian: Despite Drop, Advancement Towards Phase 3 Continues
There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroid eye disease. Initiation of the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, is expected by Q3 of 2023. Results from the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, are expected by end of 2024.